BioCentury | Dec 15, 2020
Product Development

Arvinas regains investor confidence with path forward for androgen-receptor degrader, second proof of concept for platform

...earlier in the month said the androgen receptor-degrading targeted proteolytic chimera (PROTAC) led to two PSA...
...among eight evaluable, heavily pretreated patients with mCRPC.With Monday’s data, the company now reports four PSA...
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...vaccine RV001 induced polyfunctional CD4+ T cell responses against the tumor antigen RHOC and extended PSA...
...radical prostatectomy. Results were published in Journal for ImmunoTherapy of Cancer (JITC).TARGETSGLP-1 – Glucagon-like peptide-1PSA (KLK3...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...that its androgen receptor degrader ARV-110 induced confirmed PSA...
BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

...platform, showing that AMG 160, a PSMA x CD3 bispecific antibody, reduced levels of the PSA... 24 of 35 (68.6%) evaluable castration-resistant prostate cancer patients. Half of those patients saw PSA...
BioCentury | Aug 22, 2020
Emerging Company Profile

Amphista: broadening the target space of protein degradation

...when Arvinas Inc. (NASDAQ:ARVN) showed treatment with its androgen receptor protein degrader ARV-110 led to two PSA...
BioCentury | Aug 22, 2020

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...Clinical Oncology (ASCO) meeting in May showed PSA...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

DISEASE CATEGORY: Inflammation INDICATION: Eosinophilic esophagitis Inhibiting the extracellular serine protease KLK5 or its substrate PAR2 could treat eosinophilic esophagitis, a food antigen-driven inflammatory disease. Single-cell sequencing revealed aberrant KLK5 expression in multiple cell populations...
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

...Oncology meeting showed treatment with the protein degrader of the androgen receptor led to two PSA...
BioCentury | May 13, 2020
Product Development

Arvinas unveils first efficacy signal for targeted protein degradation, points to opportunity in resistant cancers

...of eight evaluable patients treated with doses of 140 mg or higher, two achieved confirmed PSA...
...splice variant 7 CYP17 (CYP17A) - Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase PSA (KLK3) - Prostate-specific antigen Karen...
BioCentury | May 7, 2020
Product Development

ASCO preview carries MacroGenics to $1B valuation patients who received MGC018, five had reductions of at least 50% in levels of prostate-specific antigen...
Items per page:
1 - 10 of 965